Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.

BILLING CODE 4140–01–P
BILLING CODE 4140–10–P
BILLING CODE 4140–20–P
BILLING CODE 4120–01–P
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

SUMMARY: The Department of Health and Human Services (HHS) notifies federal agencies of the laboratories and Instrumented Initial Testing Facilities (IITF) currently certified to meet the standards of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines).

To become certified, an applicant laboratory or IITF must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification, a laboratory or IITF must participate in a quarterly performance testing program plus undergo periodic, on-site inspections. Laboratories and IITFs in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A HHS-certified laboratory or IITF must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA), which attests that it has met minimum standards.

In accordance with the Mandatory Guidelines dated January 23, 2017 (82 FR 7920), the following HHS-certified laboratories and IITFs meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

HHS-Certified Laboratories

ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 844–486–9226

Alere Toxicology Services, 1111 Newton St., Gretna, LA 70053, 504–361–8989/800–433–3823, (Former: Kroll Laboratory Specialists, Inc., Laboratory Specialists, Inc.)


Baptist Medical Center—Toxicology Laboratory, 11401 I–30, Little Rock, AR 72209–7056, 501–202–2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center)

Clinical Reference Laboratory, Inc., 8433 Quivira Road, Lenexa, KS 66215–2802, 800–445–6917

Cordant Health Solutions, 2617 East L Street, Tacoma, WA 98421, 800–442–0438, (Former: STERLING Reference Laboratories)

DrugScan, Inc., 200 Precision Road, Suite 200, Horsham, PA 19044, 800–235–4890


ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662–236–2609

Laboratory Corporation of America Holdings, 7207 N Gessner Road, Houston, TX 77040, 713–856–8288/800–800–2397

Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ
Laboratory Corporation of America Holdings, 1904 TW Alexander Drive, Research Triangle Park, NC 27709, 919–572–6900/800–833–3984, (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group)

Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866–827–8042/800–233–6339, (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center)

LabOne, Inc. d/b/a Quest Diagnostics, 10101 Renner Blvd., Lenexa, KS 66219, 913–888–3927/800–873–8845, (Formerly: Quest Diagnostics Incorporated; LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.)


Legacy Laboratory Services—MetroLab, 1225 NE 2nd Ave., Portland, OR 97232, 503–413–5295/800–950–5295

Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612–725–2088, Testing for Veterans Affairs Employees Only

Pacific Toxicology Laboratories, 9348 Del Oro Ave., Chatsworth, CA 91311, 800–328–6942, (Formerly: Centinela Hospital Toxicology Laboratory)

Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509–755–8991/800–541–7891x7

Phamatech, Inc., 15175 Innovation Drive, San Diego, CA 92128, 888–635–5640

Quest Diagnostics Incorporated, 1777 Montreal Circle, Tucker, GA 30084, 800–729–6432, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline BioScience Laboratories)

Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 610–631–4600/877–642–2216, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline BioScience Laboratories)

Redwood Toxicology Laboratory, 3700 Westwind Blvd., Santa Rosa, CA 95403, 800–255–2159

US Army Forensic Toxicology Drug Testing Laboratory, 2490 Wilson St., Fort George C. Meade, MD 20755–5235, 301–677–7085, Testing for Department of Defense (DoD) Employees Only

The following laboratories are voluntarily withdrawing from the National Laboratory Certification Program:


One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888–747–3774. (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory). Withdrawal effective January 18, 2019

* The Standards Council of Canada (SCC) voted to end its Laboratory Accreditation Program for Substance Abuse (LAPSA) effective May 12, 1998. Laboratories certified through that program were accredited to conduct forensic urine drug testing as required by U.S. Department of Transportation (DOT) regulations. As of that date, the certification of those accredited Canadian laboratories will continue under DOT authority. The responsibility for conducting quarterly performance testing plus periodic on-site inspections of those LAPSA-accredited laboratories was transferred to the U.S. HHS, with the HHS’ NLCP contractor continuing to have an active role in the performance testing and laboratory inspection processes. Other Canadian laboratories wishing to be considered for the NLCP may apply directly to the NLCP contractor just as U.S. laboratories do.

Upon finding a Canadian laboratory to be qualified, HHS will recommend that DOT certify the laboratory (Federal Register, July 16, 1996) as meeting the minimum standards of the Mandatory Guidelines published in the Federal Register on January 23, 2017 (82 FR 7920). After receiving DOT certification, the laboratory will be included in the monthly list of HHS-certified laboratories and participate in the NLCP certification maintenance program.

Charles P. LoDico,
Chemist.

DEPARTMENT OF HOMELAND SECURITY

Privacy Act of 1974; System of Records


ACTION: Notice of a New System of Records.

SUMMARY: In accordance with the Privacy Act of 1974, the Department of Homeland Security (DHS) proposes to establish a new DHS/U.S. Immigration and Customs Enforcement (ICE) system of records titled, “Department of Homeland Security/U.S. Immigration and Customs Enforcement—017 Angel Watch Program System of Records.” This system of records covers records collected as part of ICE’s Angel Watch Program (also referred to as Operation Angel Watch) conducted by the Child Exploitation Investigations Unit of the ICE Homeland Security Investigations Cyber Crimes Center. ICE’s Angel Watch Program is conducted as part of the Angel Watch Center (AWC), a joint initiative among ICE, DHS’s U.S. Customs and Border Protection (CBP), and the U.S. Department of Justice’s U.S. Marshals Service, as prescribed by International Megan’s Law (IML) to Prevent Child Exploitation and Other Sexual Crimes through Advanced Notification of Traveling Sex Offenders (Pub. L. 114–119).

The AWC’s mission is to prevent child sex tourism by alerting destination countries that covered sex offenders—individuals who have been convicted of sexual offenses against minors and are required to register as sex offenders with any jurisdiction in the United States—have scheduled upcoming travel to those countries. In accordance with IML, the AWC sends information to the U.S. Department of State (DoS) to facilitate that agency’s placement of unique identifiers on the passports of covered sex offenders. This system of records describes how DHS/ICE, in accordance with IML, collects and maintains records about covered sex offenders and shares certain information with DoS; the U.S. Department of Justice; other federal, state, and local agencies; and foreign countries. This newly established system of records will be included in the Department of Homeland Security’s inventory of record systems.

DATES: Submit comments on or before March 4, 2019. This new system will be effective upon publication. Routine uses will be effective March 4, 2019.